{"generic":"Florbetaben F 18","drugs":["Florbetaben F 18","Neuraceq"],"mono":{"0":{"id":"jyass0","title":"Generic Names","mono":"Florbetaben F 18"},"1":{"id":"jyass1","title":"Dosing and Indications","sub":{"0":{"id":"jyass1b4","title":"Adult Dosing","mono":"<b>PET brain study, To estimate beta-amyloid neuritic plaque density in patients with cognitive impairment:<\/b> 300 megabecquerels (8.1 millicuries) via slow IV bolus (6 sec\/mL) followed by 10 mL saline flush; MAX 30 mcg mass dose "},"1":{"id":"jyass1b5","title":"Pediatric Dosing","mono":"not indicated for use in pediatric patients "},"3":{"id":"jyass1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>PET brain study, To estimate beta-amyloid neuritic plaque density in patients with cognitive impairment<br\/>"}}},"3":{"id":"jyass3","title":"Contraindications\/Warnings","sub":[{"id":"jyass3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"jyass3b10","title":"Precautions","mono":"<ul><li>image interpretation errors may occur, especially false positives; interpretation should be independent of clinical information<\/li><li>radiopharmaceutical; ensure safe handling to reduce radiation exposure to personnel and patient<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jyass3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jyass3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jyass5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Erythema at injection site (1.7%), Injection site irritation (1.2%), Injection site pain (3.9%)<br\/>"},"6":{"id":"jyass6","title":"Drug Name Info","sub":{"0":{"id":"jyass6b17","title":"US Trade Names","mono":"Neuraceq<br\/>"},"2":{"id":"jyass6b19","title":"Class","mono":"Radiopharmaceutical Agent<br\/>"},"3":{"id":"jyass6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jyass7","title":"Mechanism Of Action","mono":"Florbetaben 18 F binds to beta-amyloid neuritic plaques in the brain. In vitro, florbetaben 18 F demonstrates binding affinity to synthetic beta-amyloid fibrils and to Alzheimer disease (AD) brain homogenate and to beta-amyloid plaques in post-mortem AD brain sections. In vivo, quantitative correlation was not assessed in end-of-life patients between florbetaben 18 F uptake in cortical grey matter and the beta-amyloid deposition in autopsied samples.<br\/>"},"8":{"id":"jyass8","title":"Pharmacokinetics","sub":{"1":{"id":"jyass8b24","title":"Distribution","mono":"<ul><li>Protein binding: greater than 98.5%<\/li><li>Brain: 6%<\/li><\/ul>"},"2":{"id":"jyass8b25","title":"Metabolism","mono":"<ul><li>Liver: extensive<\/li><li>polar metabolites<\/li><\/ul>"},"3":{"id":"jyass8b26","title":"Excretion","mono":"Renal, 30% <br\/>"},"4":{"id":"jyass8b27","title":"Elimination Half Life","mono":"approximately 1 hour <br\/>"}}},"9":{"id":"jyass9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>radiation protection precautions in accordance with national regulations must be taken; use waterproof gloves and maintain adequate shielding<\/li><li>do not dilute<\/li><li>measure with a dose calibrator immediately prior to administration<\/li><li>test catheter patency with saline prior to administration<\/li><li>administer by slow IV bolus injection (6 sec\/mL) in large arm vein, followed by a 10-mL saline flush to ensure full delivery of the dose<\/li><li>any unused portion must be disposed of according to local requirements<\/li><\/ul>"},"10":{"id":"jyass10","title":"Monitoring","mono":"<ul><li>enhancement and identification of beta-amyloid plaques upon positron emission tomography (PET) imaging of the brain is indicative of efficacy.<\/li><li>pregnancy status; prior to initiating therapy in women of childbearing potential<\/li><\/ul>"},"13":{"id":"jyass13","title":"Clinical Teaching","mono":"<ul><li>Instruct patients of childbearing potential that drug may cause fetal harm.<\/li><li>Advise breastfeeding women to interrupt breastfeeding for 24 hours following injection. Discard expressed feeds during this time.<\/li><li>Side effects may include injection site pain, irritation, or erythema.<\/li><\/ul>"}}}